Guidance on Index Case
The Executive Yuan unveiled the “Taiwan Biotech Take-off Diamond Action Plan” to boost the research and development capability for medical product commercialization. In light of this strategic plan, the CDE provides advices on regulatory requirements which should be considered by all new drug developers in their R&D processes.
Consultation Services For Drugs
In light of the government’s policy to promote the biotech industry and to create the industry’s competitive edge, the CDE undertakes a mission to provide the bio-pharmaceutical industry and academic research institutes in Taiwan the most comprehensive regulatory consultation services on drug development (including new drugs, generic drugs, botanical new drugs, bio-pharmaceuticals and emerging biotech products for cell or gene therapy).